A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 167, Issue 3, Pages 366-375
Publisher
Wiley
Online
2014-08-19
DOI
10.1111/bjh.13056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
- (2013) Samantha Pozzi et al. BONE
- Emerging biological insights and novel treatment strategies in multiple myeloma
- (2012) Massimo Gentile et al. EXPERT OPINION ON EMERGING DRUGS
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
- (2011) Gareth J Morgan et al. LANCET ONCOLOGY
- AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model
- (2011) H Yao et al. Blood Cancer Journal
- Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
- (2010) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Characterization of Wnt/β-catenin signalling in osteoclasts in multiple myeloma
- (2009) Ya-Wei Qiang et al. BRITISH JOURNAL OF HAEMATOLOGY
- DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in Multiple Myeloma
- (2009) Olivia Lemaire et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
- (2008) Y.-W. Qiang et al. BLOOD
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
- (2008) Y.-W. Qiang et al. BLOOD
- Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
- (2008) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment
- (2008) Ulrike Heider et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
- (2008) Deborah J Heath et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair
- (2008) Carmen E. Macsai et al. JOURNAL OF CELLULAR PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More